Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 7/20 | 1.00 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 1.00 |
| ▸ | GAA | P10253 | 2/20 | 1.00 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.68 |
| ▸ | POLB | P06746 | 2/20 | 0.68 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.62 |
| ▸ | RAD52 | P43351 | 1/20 | 0.62 |
| ▸ | HTT | P42858 | 2/20 | 0.60 |
| ▸ | ALDH3A1 | P30838 | 1/20 | 0.58 |
| ▸ | ALDH1A3 | P47895 | 1/20 | 0.58 |
| ▸ | MEN1 | O00255 | 2/20 | 0.53 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.53 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.51 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.51 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.50 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.50 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.50 |
| ▸ | THRB | P10828 | 1/20 | 0.50 |
| ▸ | LGMN | Q99538 | 1/20 | 0.50 |
| ▸ | AKR1C3 | P42330 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29715972 | 1.00 | MAPT (1.00) | MAPTSMN1; SMN2GAAALDH1A1POLB | |
| SCHEMBL24876694 | 0.93 | MAPT (0.87) | MAPTSMN1; SMN2GAAALDH1A1POLB | |
| SCHEMBL24507284 | 0.87 | MAPT (0.77) | MAPTSMN1; SMN2GAAALDH1A1POLB | |
| SCHEMBL15358686 | 0.86 | ALDH1A1 (0.81) | MAPTSMN1; SMN2GAAALDH1A1POLB | |
| SCHEMBL6052293 | 0.85 | MAPT (0.72) | MAPTSMN1; SMN2GAAALDH1A1POLB | |
| SCHEMBL4377045 | 0.83 | MAPT (0.71) | MAPTSMN1; SMN2GAAALDH1A1POLB | |
| SCHEMBL31491393 | 0.83 | MAPT (0.71) | MAPTSMN1; SMN2GAAALDH1A1POLB | |
| SCHEMBL76629 | 0.82 | ALDH1A1 (0.96) | MAPTSMN1; SMN2GAAALDH1A1POLB | |
| SCHEMBL18452907 | 0.81 | MAPT (0.69) | MAPTSMN1; SMN2GAAALDH1A1POLB | |
| SCHEMBL160768 | 0.81 | ALDH1A1 (1.00) | MAPTSMN1; SMN2GAAALDH1A1POLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 297 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3204453-B1 | LOW MOLECULAR WEIGHT GRAFT POLYMER FOR SCALE INHIBITOR | HERCULES LLC (US) | 2019-08-28 | — | — | EP | claimed |
| US-9914790-B2 | Low molecular weight graft polymer for scale inhibitor | HERCULES LLC (US) | 2018-03-13 | — | — | US | claimed |
| EP-3204453-A1 | LOW MOLECULAR WEIGHT GRAFT POLYMER FOR SCALE INHIBITOR | Hercules LLC (US) | 2017-08-16 | — | — | EP | claimed |
| EP-2611797-B1 | QUINOLINE OR QUINAZOLINE DERIVATIVES WITH APOPTOSIS INDUCING ACTIVITY ON CELLS | HANMI SCIENCE CO LTD (KR) | 2016-12-28 | — | — | EP | claimed |
| WO-2016057299-A1 | LOW MOLECULAR WEIGHT GRAFT POLYMER FOR SCALE INHIBITOR | HERCULES INCORPORATED (US) | 2016-04-14 | — | — | WO | claimed |
| US-20160096908-A1 | LOW MOLECULAR WEIGHT GRAFT POLYMER FOR SCALE INHIBITOR | ISP INVESTMENTS LLC | 2016-04-07 | — | — | US | claimed |
| US-8835458-B2 | Quinoline or quinazoline derivatives with apoptosis inducing activity on cells | HANMI SCIENCE CO., LTD (KR) | 2014-09-16 | — | — | US | claimed |
| EP-2611797-A2 | QUINOLINE OR QUINAZOLINE DERIVATIVES WITH APOPTOSIS INDUCING ACTIVITY ON CELLS | Hanmi Science Co., Ltd. (KR) | 2013-07-10 | — | — | EP | claimed |
| US-20130165386-A1 | QUINOLINE OR QUINAZOLINE DERIVATIVES WITH APOPTOSIS INDUCING ACTIVITY ON CELLS | HANMI SCIENCE CO., LTD (KR) | 2013-06-27 | — | — | US | claimed |
| US-20120196849-A1 | COMPOUNDS AND COMPOSITIONS AS HEDGEHOG PATHWAY MODULATORS | IRM LLC (BM) | 2012-08-02 | — | — | US | claimed |
| US-20100197659-A1 | BIPHENYLCARBOXAMIDE DERIVATIVES AS HEDGEHOD PATHWAY MODULATORS | IRM LLC (BM) | 2010-08-05 | — | — | US | claimed |
| EP-2162190-A1 | BIPHENYLCARBOXAMIDE DERIVATIVES AS HEDGEHOG PATHWAY MODULATORS | IRM LLC (BM) | 2010-03-17 | — | — | EP | claimed |
| EP-2150532-A1 | PIPERAZINE COMPOUNDS FOR THE INHIBITION OF HAEMATOPOIETIC PROSTAGLANDIN D SYNTHASE | Evotec AG (DE) | 2010-02-10 | — | — | EP | claimed |
| US-20090203666-A1 | COMPOUNDS AND COMPOSITIONS AS HEDGEHOG PATHWAY MODULATORS | IRM LLC (BM) | 2009-08-13 | — | — | US | claimed |
| CN-101437800-A | Compounds and compositions as HEDGEHOG pathway modulators | IRM LLC (BM) | 2009-05-20 | — | — | CN | claimed |
| WO-2008154259-A1 | BIPHENYLCARBOXAMIDE DERIVATIVES AS HEDGEHOG PATHWAY MODULATORS | IRM LLC (BM) | 2008-12-18 | — | — | WO | claimed |
| WO-2008122787-A1 | PIPERAZINE COMPOUNDS FOR THE INHIBITION OF HAEMATOPOIETIC PROSTAGLANDIN D SYNTHASE | EVOTEC AG (DE) | 2008-10-16 | — | — | WO | claimed |
| US-20050182050-A1 | Therapeutic heterocyclic compounds | ASTRAZENECA AB (SE) | 2005-08-18 | — | — | US | claimed |
| US-6812225-B2 | PYSCHOLOGICAL DISORDERS; ANTIDEPRESSANTS | ASTRAZENECA AB (SE) | 2004-11-02 | — | — | US | claimed |
| US-20030013708-A1 | Therapeutic heterocyclic compounds | ASTRAZENECA AB (SE) | 2003-01-16 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100197659-A1 | BIPHENYLCARBOXAMIDE DERIVATIVES AS HEDGEHOD PATHWAY MODULATORS | GLI1, SHH, GLI2 | MAPT 4534/4885SMN1; SMN2 3424/4885GAA 2972/4885 |
| US-20090203666-A1 | COMPOUNDS AND COMPOSITIONS AS HEDGEHOG PATHWAY MODULATORS | GLI1, SHH, SMO | MAPT 4520/4885SMN1; SMN2 3605/4885GAA 2406/4885 |
| US-20050182050-A1 | Therapeutic heterocyclic compounds | HTR1B, HTR1D, HTR1A | MAPT 653/4885SMN1; SMN2 594/4885GAA 382/4885 |
| US-20030013708-A1 | Therapeutic heterocyclic compounds | HTR1A, HTR1D, HTR1B | MAPT 661/4885SMN1; SMN2 599/4885GAA 411/4885 |
| US-20120196849-A1 | COMPOUNDS AND COMPOSITIONS AS HEDGEHOG PATHWAY MODULATORS | GLI1, SHH, SMO | MAPT 4520/4885SMN1; SMN2 3605/4885GAA 2406/4885 |
| US-20130165386-A1 | QUINOLINE OR QUINAZOLINE DERIVATIVES WITH APOPTOSIS INDUCING ACTIVITY ON CELLS | CASP7, API5, BAX | MAPT 288/4885SMN1; SMN2 930/4885GAA 2962/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.